Division faculty collaborate with cancer researchers nationwide to develop and evaluate the effectiveness of different cancer detection, prevention and treatment options. With funding and support from the IU Simon Comprehensive Cancer Center, National Institute of Health (NIH) and other prestigious funding sources, the division produces ground-breaking and practice-changing research.
Active Research
Principal Investigator: Lisa Landrum, MD, PhD
To characterize the real-world TTD, TTNT, reasons for discontinuation, and dose management of 1LM niraparib in advanced epithelial OC patients in the real world
Principal Investigator: Sharon Robertson, MD, MPH
The purpose of this study is to evaluate anti-tumor efficacy of VB10.16 + placebo and VB10.16 + atezolizumab.
Principal Investigator: Jessica Parker, MD
Contact: Ashley Sheets, CRPS
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer).
Principal Investigator: Lisa Landrum, MD, PhD
This is a 2-part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo. Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.
Principal Investigator: Lisa Landrum, MD, PhD
Contact: iutrials@iu.edu
This is a Phase III randomized, double-blind, multi-center study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
IU Lead: Sharon Robertson, MD, MPH
Contact: Ashley Sheets, CRPS
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Principal Investigator: Lisa Landrum, MD, PhD
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Principal Investigator: Jessica Parker, MD
Contact: iutrials@iu.edu
GLORIOSA is a Phase 3 multicenter, open-label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Principal Investigator: Lisa Landrum, MD, PhD
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
Principal Investigator: Sharon Robertson, MD, MPH
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT.
Principal Investigator: Lisa Landrum, MD, PhD
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.